Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study
- 154 Downloads
Taxane/platinum (TP)-based combination chemotherapy is standard for the treatment of metastatic or recurrent cervical cancer. The aim of this study was to investigate the efficacy of postoperative TP therapy in early stage cervical cancer.
A retrospective review of patients with FIGO IB–IIB stage cervical cancer who were treated with radical hysterectomy and displayed surgical-pathological risk factors was performed. 122 patients were identified between 2003 and 2012. Survival was analyzed by Kaplan–Meier method and compared by the log-rank test. The Cox proportional hazards model was used to investigate predictors of survival.
The median follow-up period was 82.4 months. The postoperative adjuvant therapy was TP in 82 (67.2%) patients, other chemotherapies in 10 (8.2%), radiotherapy (RT) in 25 (20.5%), and no further therapy (NFT) in 5 (4.1%). Survival was analyzed using 4 subgroups according to the postoperative adjuvant therapy. The estimated 5-year overall survival was 95.1% in the TP group, 90.0% in the other chemotherapy group, 78.9% in the RT group, and 100% in the NFT group. No significant difference of survival was observed in the subgroups. However, when analyzing only patients who displayed high-risk factors, non-TP adjuvant therapy (including RT and other chemotherapies) was independently associated with shorter survival on multivariate analysis. In the TP group, multivariate analysis revealed that a positive surgical margin was a significant predictor of shorter survival.
Postoperative TP is effective in patients with surgically treated early stage cervical cancer. In these populations, a positive surgical margin could be associated with poor prognosis.
KeywordsCervical cancer Recurrence Survival Adjuvant therapy Radical hysterectomy Taxane/platinum
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
- 1.Organization WH World Health Organization. http://www.who.int/cancer/prevention/diagnosis-screening/cervical-cancer/en/. Accessed 24 May 2017
- 2.Cancer Research UK. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer. Accessed 28 May 2017
- 3.National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/statfacts/html/cervix.html. Accessed 25 May 2017
- 4.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, Cervical Cancer. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed 30 May 2017
- 8.Sedlis A, Bundy BN, Rotman MZ et al (1999) A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a Gynecologic Oncology Group Study. Gynecol Oncol 73(2):177–183CrossRefPubMedGoogle Scholar
- 38.Duenas-Gonzalez A, Lopez-Graniel C, Gonzalez-Enciso A et al (2003) A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation. Ann Oncol 14(8):1278–1284CrossRefPubMedGoogle Scholar
- 41.Okazawa M, Mabuchi S, Isohashi F et al (2013) Impact of the addition of concurrent chemotherapy to pelvic radiotherapy in surgically treated stage IB1-IIB cervical cancer patients with intermediate-risk or high-risk factors: a 13-year experience. Int J Gynecol Cancer 23(3):567–575CrossRefPubMedGoogle Scholar
- 45.Mabuchi S, Isohashi F, Yokoi T et al (2016) A phase II study of postoperative concurrent carboplatin and paclitaxel combined with intensity-modulated pelvic radiotherapy followed by consolidation chemotherapy in surgically treated cervical cancer patients with positive pelvic lymph nodes. Gynecol Oncol 141(2):240–246CrossRefPubMedGoogle Scholar
- 47.NCT01101451. https://clinicaltrials.gov/ct2/show/NCT01101451. Accessed 11 June 2017